Skip to main content

Table 2 Baseline characteristics of the study cohort, for associations between variables depending on the score groups

From: Biomarkers-based personalized follow-up in chronic heart failure improves patient’s outcomes and reduces care associate cost

 

Total (N = 192)

Low-risk (n=117)

Medium-risk (n = 63)

High-risk (n = 12)

p value

Age (years)

65 [57–73]

60 [53–69]

72 [66–77]

73 [65–81]

< 0.001

Gender (female)

20.3

23.9

14.3

16.7

0.292

Arterial hypertension

69.3

58.1

85.7

91.7

< 0.001

Dyslipidemia

64.1

52.1

82.5

83.3

< 0.001

Diabetes mellitus

37.5

25.6

54.0

66.7

< 0.001

COPD

20.3

13.7

30.2

33.3

0.016

Chronic renal failure

25.8

13.0

42.9

58.3

< 0.001

Previous atrial fibrillation

34.9

22.2

50.8

75.0

< 0.001

LVEF

30 [27–36]

30 [28–36]

30 [28–36]

27 [25–32]

0.116

Ischemic etiology

50

40.2

65.1

66.7

0.003

Duration of HF (years)

3 [2–5

2 [2–4]

5 [3–7]

6 [3–9]

< 0.001

Functional class

 NYHA 1

36.1

44.8

23.8

16.7

 

 NYHA 2

47.6

46.6

52.4

33.3

< 0.001

 NYHA 3

16.2

8.6

23.8

50.0

 

ICD/CRT

12.0

5.1

20.6

33.3

0.001

Heart rate

61 [55–70]

60 [55–66]

63 [60–70]

64 [59–80]

0.107

NT-proBNP (pg/mL)

984 [393–2334]

599 [244–1211]

2045 [860–3664]

3494 [1503–8541]

< 0.001

hs T-Troponin (ng/mL)

15 [8–27]

11 [6–16]

24 [17–40]

53 [39–68]

< 0.001

Glomerular filtration (mL/min/1.73 m2)

76.07 ± 27.75

86.36 ± 23.66

62.54 ± 22.59

46.75 ± 38.50

< 0.001

Sodium (mEq/L)

141 [140–143]

141 [140–143]

142 [141–144]

139 [138–141]

0.005

ACEI/ARB

60.4

62.4

58.7

50.0

0.667

ARNI

38.0

35.9

39.7

50.0

0.598

Betablockers

95.8

97.4

95.2

83.3

0.064

MRA

78.1

76.1

82.5

75.0

0.584

Diuretics

67.7

47.0

100.0

100.0

< 0.001

  1. Data are presented as median and Interquartile Range [p25–p75] for continuous variables and percentages for categorical variables
  2. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNI angiotensin receptor-neprilysin inhibitor, COPD chronic obstructive pulmonary disease, CRT cardiac resynchronization therapy, ICT implantable cardioverter defibrillators, LVEF left ventricular ejection fraction, HF heart failure, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association, NT-proBNP N-terminal pro-brain natriuretic peptide